by John R. Fischer
, Senior Reporter | July 17, 2019
C-RAD has granted Elekta the right to distribute its surface image-guided radiation therapy (SIGRT) technology to providers for use in stereotactic radiosurgery, stereotactic body radiotherapy, and motion management.
Beginning in the North American and Mexican markets, the agreement brings together the benefits of C-RAD’s Catalyst HD system, which integrates with Elekta linacs, and those of Elekta’s Versa HD high-definition dynamic radiosurgery solution.
"Accuracy is key when escalating dose," Dee Mathieson, senior vice president of treatment solutions at Elekta, told HCB News. "The X-ray products complement the patient set up and motion management capabilities of the Versa HD to give confidence to the clinicians."
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
A non-surgical treatment, stereotactic radiotherapy is used to treat functional abnormalities and small tumors within the brain. Stereotactic body radiotherapy is used to treat the same issues within the body.
Capable of treating all parts and organs in the body, Versa HD customizes high-energy X-rays to conform to a tumor’s shape and destroy cancer cells while sparing surrounding healthy tissue.
In addition to providing gross patient positioning and postural positioning, the Catalyst system is equipped with respiratory motion management and other capabilities that extend the value of Elekta’s Versa HD system.
“Our priority is always to provide a high level of patient safety and comfort while ensuring an efficient and seamless workflow for clinicians with the greatest degree of confidence,” said Maurits Wolleswinkel, president of linac solutions at Elekta, in a statement. This collaboration with C-RAD supports Elekta’s linear accelerators — in particular, Versa HD — to meet the growing demand for SIGRT.”
The agreement is now in use in the North American and Mexican markets, with plans in place to eventually expand it to other markets.
C-RAD did not respond for comment.